bioAffinity's CyPath® Lung Test Prevents Unnecessary Biopsy in High-Risk Patient

summarizeSummary

bioAffinity Technologies announced a new clinical case study where its CyPath® Lung diagnostic test successfully helped a physician avoid an unnecessary biopsy for a high-risk patient, validating the test's utility in pulmonary nodule management.

check_boxKey Events · Product Development and Regulatory · BIAF

• New Clinical Case Study Released

  bioAffinity Technologies announced a new clinical case study illustrating how its CyPath® Lung diagnostic test helped determine next steps for a high-risk patient with a suspicious pulmonary nodule.

• Avoided Unnecessary Biopsy

  Despite imaging and risk models suggesting a high likelihood of cancer, CyPath® Lung's 'Unlikely Malignancy' result prompted a follow-up scan, which showed the nodule had completely resolved, preventing a risky and costly biopsy.

• Reinforces Product Utility

  The case study highlights CyPath® Lung's value in assisting physicians with pulmonary nodule management by providing objective data to confidently defer unnecessary invasive procedures, especially for patients with complicating health conditions.

auto_awesomeAnalysis · BIAF · Industrial Applications And Services

This 8-K highlights a new clinical case study demonstrating the real-world utility of bioAffinity Technologies' CyPath® Lung diagnostic test. The case illustrates how the noninvasive test helped a physician confidently defer a potentially risky and unnecessary biopsy for a high-risk patient, despite imaging and risk models suggesting a high likelihood of cancer. This positive clinical validation is crucial for a company facing a going concern warning, as it reinforces the value proposition and potential for market adoption of its core product, CyPath® Lung. This follows recent positive news regarding sales growth and conference presentations for CyPath Lung, building a stronger commercial narrative.